Avance Clinical, a full-service Australia headquartered contract research organisation (CRO) focused on accelerating clinical development for biotech sponsors, has announced the acquisition of LumaBridge, a specialised US-based clinical CRO with deep expertise in oncology trials.
This strategic acquisition expands Avance’s existing US presence and marks a significant milestone in accelerating the company’s growth in oncology, the largest and fastest-growing therapeutic area in global R&D. Both organisations share a commitment to deliver high quality, innovative and efficient oncology clinical trials that accelerate the development of next-generation therapies to patients worldwide.
LumaBridge will form the foundation of Avance’s global Oncology Center of Excellence. The LumaBridge team brings experienced oncology leadership, strong US operational capabilities, and a proven track record of delivering complex cancer studies for global biotech and pharmaceutical clients across early and later phase clinical development.
The combination enhances Avance’s ability to support oncology development, from early Phase I studies through to global later phase programmes. Clients will benefit from an expanded US footprint, deeper medical, scientific, and regulatory expertise, and strong site and investigator relationships. The acquisition also strengthens Avance’s ability to provide clients with access to the Phase I market in Australia and New Zealand and further taking the innovations into Phase II and III trials through the company’s GlobalReady programme.
